These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 24900539)

  • 21. Discovery of novel orally bioavailable GPR40 agonists.
    Lu H; Fei H; Yang F; Zheng S; Hu Q; Zhang L; Yuan J; Feng J; Sun P; Dong Q
    Bioorg Med Chem Lett; 2013 May; 23(10):2920-4. PubMed ID: 23582779
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Linoleic acid activates GPR40/FFA1 and phospholipase C to increase [Ca2+]i release and insulin secretion in islet beta-cells.
    Zhou YJ; Song YL; Zhou H; Li Y
    Chin Med Sci J; 2012 Mar; 27(1):18-23. PubMed ID: 22734209
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Discovery of novel pyrrole-based scaffold as potent and orally bioavailable free fatty acid receptor 1 agonists for the treatment of type 2 diabetes.
    Li Z; Pan M; Su X; Dai Y; Fu M; Cai X; Shi W; Huang W; Qian H
    Bioorg Med Chem; 2016 May; 24(9):1981-7. PubMed ID: 27020683
    [TBL] [Abstract][Full Text] [Related]  

  • 24. GPR40 full agonism exerts feeding suppression and weight loss through afferent vagal nerve.
    Ueno H; Ito R; Abe SI; Ogino H; Maruyama M; Miyashita H; Miyamoto Y; Moritoh Y; Tsujihata Y; Takeuchi K; Nishigaki N
    PLoS One; 2019; 14(9):e0222653. PubMed ID: 31525244
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Activity of dietary fatty acids on FFA1 and FFA4 and characterisation of pinolenic acid as a dual FFA1/FFA4 agonist with potential effect against metabolic diseases.
    Christiansen E; Watterson KR; Stocker CJ; Sokol E; Jenkins L; Simon K; Grundmann M; Petersen RK; Wargent ET; Hudson BD; Kostenis E; Ejsing CS; Cawthorne MA; Milligan G; Ulven T
    Br J Nutr; 2015 Jun; 113(11):1677-88. PubMed ID: 25916176
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [A New Pain Regulatory System via the Brain Long Chain Fatty Acid Receptor GPR40/FFA1 Signal].
    Nakamoto K
    Yakugaku Zasshi; 2017; 137(2):199-204. PubMed ID: 28154332
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Discovery of the imidazole-derived GPR40 agonist AM-3189.
    Ma Z; Lin DC; Sharma R; Liu J; Zhu L; Li AR; Kohn T; Wang Y; Liu JJ; Bartberger MD; Medina JC; Zhuang R; Li F; Zhang J; Luo J; Wong S; Tonn GR; Houze JB
    Bioorg Med Chem Lett; 2016 Jan; 26(1):15-20. PubMed ID: 26620255
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Progress in the discovery and development of small-molecule modulators of G-protein-coupled receptor 40 (GPR40/FFA1/FFAR1): an emerging target for type 2 diabetes.
    Bharate SB; Nemmani KV; Vishwakarma RA
    Expert Opin Ther Pat; 2009 Feb; 19(2):237-64. PubMed ID: 19441920
    [TBL] [Abstract][Full Text] [Related]  

  • 29. CNX-011-67, a novel GPR40 agonist, enhances glucose responsiveness, insulin secretion and islet insulin content in n-STZ rats and in islets from type 2 diabetic patients.
    Sunil V; Verma MK; Oommen AM; Sadasivuni M; Singh J; Vijayraghav DN; Chandravanshi B; Shetty J; Biswas S; Dandu A; Moolemath Y; Venkataranganna MV; Somesh BP; Jagannath MR
    BMC Pharmacol Toxicol; 2014 Mar; 15():19. PubMed ID: 24666736
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A selective GPR40 (FFAR1) agonist LY2881835 provides immediate and durable glucose control in rodent models of type 2 diabetes.
    Chen Y; Song M; Riley JP; Hu CC; Peng X; Scheuner D; Bokvist K; Maiti P; Kahl SD; Montrose-Rafizadeh C; Hamdouchi C; Miller AR
    Pharmacol Res Perspect; 2016 Dec; 4(6):e00278. PubMed ID: 28097011
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Identification of fused-ring alkanoic acids with improved pharmacokinetic profiles that act as G protein-coupled receptor 40/free fatty acid receptor 1 agonists.
    Negoro N; Sasaki S; Ito M; Kitamura S; Tsujihata Y; Ito R; Suzuki M; Takeuchi K; Suzuki N; Miyazaki J; Santou T; Odani T; Kanzaki N; Funami M; Tanaka T; Yasuma T; Momose Y
    J Med Chem; 2012 Feb; 55(4):1538-52. PubMed ID: 22242551
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Acute administration of GPR40 receptor agonist potentiates glucose-stimulated insulin secretion in vivo in the rat.
    Doshi LS; Brahma MK; Sayyed SG; Dixit AV; Chandak PG; Pamidiboina V; Motiwala HF; Sharma SD; Nemmani KV
    Metabolism; 2009 Mar; 58(3):333-43. PubMed ID: 19217448
    [TBL] [Abstract][Full Text] [Related]  

  • 33. GPR40 partial agonist MK-2305 lower fasting glucose in the Goto Kakizaki rat via suppression of endogenous glucose production.
    Miller C; Pachanski MJ; Kirkland ME; Kosinski DT; Mane J; Bunzel M; Cao J; Souza S; Thomas-Fowlkes B; Di Salvo J; Weinglass AB; Li X; Myers RW; Knagge K; Carrington PE; Hagmann WK; Trujillo ME
    PLoS One; 2017; 12(5):e0176182. PubMed ID: 28542610
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Selective small-molecule agonists of G protein-coupled receptor 40 promote glucose-dependent insulin secretion and reduce blood glucose in mice.
    Tan CP; Feng Y; Zhou YP; Eiermann GJ; Petrov A; Zhou C; Lin S; Salituro G; Meinke P; Mosley R; Akiyama TE; Einstein M; Kumar S; Berger JP; Mills SG; Thornberry NA; Yang L; Howard AD
    Diabetes; 2008 Aug; 57(8):2211-9. PubMed ID: 18477808
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Discovery of a structurally novel, potent, and once-weekly free fatty acid receptor 1 agonist for the treatment of diabetes.
    Wang B; Cai Z; Yao H; Jiao S; Chen S; Yang Z; Huang W; Ren Q; Cao Z; Chen Y; Zhang L; Li Z
    Eur J Med Chem; 2023 Jan; 245(Pt 1):114883. PubMed ID: 36343410
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Discovery of Potent and Orally Bioavailable Dihydropyrazole GPR40 Agonists.
    Shi J; Gu Z; Jurica EA; Wu X; Haque LE; Williams KN; Hernandez AS; Hong Z; Gao Q; Dabros M; Davulcu AH; Mathur A; Rampulla RA; Gupta AK; Jayaram R; Apedo A; Moore DB; Liu H; Kunselman LK; Brady EJ; Wilkes JJ; Zinker BA; Cai H; Shu YZ; Sun Q; Dierks EA; Foster KA; Xu C; Wang T; Panemangalore R; Cvijic ME; Xie C; Cao GG; Zhou M; Krupinski J; Whaley JM; Robl JA; Ewing WR; Ellsworth BA
    J Med Chem; 2018 Feb; 61(3):681-694. PubMed ID: 29316397
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Potentiation of insulin secretion and improvement of glucose intolerance by combining a novel G protein-coupled receptor 40 agonist DS-1558 with glucagon-like peptide-1 receptor agonists.
    Nakashima R; Yano T; Ogawa J; Tanaka N; Toda N; Yoshida M; Takano R; Inoue M; Honda T; Kume S; Matsumoto K
    Eur J Pharmacol; 2014 Aug; 737():194-201. PubMed ID: 24858371
    [TBL] [Abstract][Full Text] [Related]  

  • 38. GPR40 protein levels are crucial to the regulation of stimulated hormone secretion in pancreatic islets. Lessons from spontaneous obesity-prone and non-obese type 2 diabetes in rats.
    Meidute Abaraviciene S; Muhammed SJ; Amisten S; Lundquist I; Salehi A
    Mol Cell Endocrinol; 2013 Dec; 381(1-2):150-9. PubMed ID: 23911664
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Activation of FFA1 mediates GLP-1 secretion in mice. Evidence for allosterism at FFA1.
    Xiong Y; Swaminath G; Cao Q; Yang L; Guo Q; Salomonis H; Lu J; Houze JB; Dransfield PJ; Wang Y; Liu JJ; Wong S; Schwandner R; Steger F; Baribault H; Liu L; Coberly S; Miao L; Zhang J; Lin DC; Schwarz M
    Mol Cell Endocrinol; 2013 Apr; 369(1-2):119-29. PubMed ID: 23403053
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The fatty acid receptor FFA1/GPR40 a decade later: how much do we know?
    Mancini AD; Poitout V
    Trends Endocrinol Metab; 2013 Aug; 24(8):398-407. PubMed ID: 23631851
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.